Download a complete bibliography from each of our ongoing investigational programs below.
Evaluation of the Spontaneous Mutation Frequencies of SPR719 Alone and in Combination with Other Agents Used to Treat Mycobacterium avium Complex Pulmonary Disease
SPR720
Intrapulmonary pharmacokinetics of SPR719 following oral administration of SPR720 to healthy volunteers
Tebipenem HBR
Effect of tebipenem pivoxil hydrobromide on the normal gut microbiota of a healthy adult population in Sweden: a randomised controlled trial
SPR720
Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection
Serum Cell-free DNA-based Detection of Mycobacterium Avium Complex Infection
SPR720
Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720
Tebipenem HBR
Impact of antibiotic pharmacokinetics in urine on recurrent bacteriuria following treatment of complicated urinary tract infections
Tebipenem HBR
Clinical and microbiological outcomes for Enterobacterales uropathogens in the Phase 3 ADAPT-PO Study of oral tebipenem pivoxil hydrobromide
Enterobacterales Resistance Patterns for Extended Spectrum β lactamase (ESBL) Positive and Multidrug Resistant (MDR) Urine Isolates Collected and Tested from 295 Outpatient US Facilities in 2019
Tebipenem HBR
Effectiveness of TBP PI HBr in Patients with Instrumentation, Anatomic or Functional Abnormalities: Secondary Analysis from ADAPT PO
The Economic Burden of Adverse Events Requiring Acute Care Service from Outpatient Parenteral Antibiotic Treatment (OPAT)
Tebipenem HBR
The 30-day economic burden of newly diagnosed complicated urinary tract infections in Medicare patients.
Tebipenem HBR
Sun Z, Su L, Cotroneo N, et al. Evaluation of Tebipenem Hydrolysis by β-Lactamases Prevalent in Complicated Urinary Tract Infections. Antimicrob Agents Chemother. 2022 May 2:e0239621
Tebipenem HBR
Lodise T, Nowak M, Rodriguez M. The 30-Day Economic Burden of Newly Diagnosed Complicated Urinary Tract Infections in Medicare Fee-for-Service Patients Who Resided in the Community. Antibiotics 2022; 11(5):578.
Tebipenem HBR
First performance study of ETEST TBP (Tebipenem) for Minimum Inhibitory Concentration (MIC) Determination for Enterobacterales
Tebipenem HBR
Effect of tebipenem on the normal gut microbiota of healthy adult population.
Tebipenem HBR
Plasma pharmacokinetics and intrapulmonary penetration of tebipenem in healthy subjects
Tebipenem HBR
Activity of oral tebipenem against resistant Escherichia coli collected from urinary tract infections in Europe in 2020
Tebipenem HBR
Efficacy of tebipenem pivoxil hydrobromide in patients with complicated urinary tract infection and associated bacteremia
Tebipenem HBR
Relationship between receipt of prior antibiotics and presence of antibiotic resistance among adult outpatients with complicated urinary tract infection
Tebipenem HBR
Tebipenem pivoxil hydrobromide: Safety and tolerability profile of the first oral carbapenem for complicated urinary tract infection and acute pyelonephritis
Tebipenem HBR
Patel G, Rodvold KA, Gupta VK, et al. Pharmacokinetics of Oral Tebipenem Pivoxil Hydrobromide in Subjects with Various Degrees of Renal Impairment. Antimicrob Agents Chemother. 2022 Apr 14. doi: 10.1128/aac.02407-21. Epub ahead of print.
Tebipenem HBR
Gupta VK, Patel G, Gasink L, et al. Bioequivalence of Two Oral Formulations of Tebipenem Pivoxil Hydrobromide in Healthy Subjects. Clin Transl Sci. 2022 Apr 11. doi: 10.1111/cts.13280. Epub ahead of print.
Tebipenem HBR
Clinical stability indicators between ertapenem and tebipenem pivoxil, an oral carbapenem, in hospitalized adults with complicated urinary tract infection
Tebipenem HBR
Oral tebipenem pivoxil is non-inferior to IV ertapenem in complicated urinary tract infection and acute pyelonephritis: ADAPT-PO Study
Tebipenem HBR
Eckburg PB, Muir L, Critchley IA, et al. Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection. N Engl J Med 2022;386:1327-38.
Tebipenem HBR
Zilberberg MD, Nathanson BH, Sulham K, Shorr AF. Descriptive epidemiology and outcomes of emergency department visits with complicated urinary tract infections in the United States, 2016-2018. J Am Coll Emerg Physicians Open. 2022 Mar 17;3(2):e12694
SPR720
Aragaw WW, Cotroneo N, Stokes S, Pucci M, Critchley I, Gengenbacher M, Dick T. In Vitro Resistance against DNA Gyrase Inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus. Microbiol Spectr. 2022 Jan 12;10(1):e0132121.
Tebipenem HBR
Zilberberg MD, Nathanson BH, Sulham K, Shorr AF. Descriptive Epidemiology and Outcomes of Hospitalizations With Complicated Urinary Tract Infections in the United States, 2018. Open Forum Infect Dis. 2022 Jan 10;9(1):ofab591
Tebipenem HBR
Epidemiology and 12-month antibiotic use in the outpatient setting among adult patients with complicated urinary tract infections: a retrospective database analysis
Tebipenem HBR
Molecular epidemiology of Escherichia coli causing urinary tract infections in United States and in vitro activity of tebipenem, including against strain lineage and resistant subsets (2018–2020)
Tebipenem HBR
High prevalence of fluoroquinolone-resistant urinary tract infection among US emergency department patients diagnosed with UTI, 2018-2020
Tebipenem HBR
In vitro activity of tebipenem and comparators against Enterobacterales collected from patients with bloodstream infections as part of the 2019 global STEWARD surveillance program
Tebipenem HBR
In vitro activity of tebipenem against relevant clinical isolates in the presence of pulmonary surfactant
Tebipenem HBR
In vitro analysis of AmpC β-lactamase induction by tebipenem in Enterobacterales and Pseudomonas aeruginosa
Tebipenem HBR
Oral tebipenem as step-down therapy following intravenous ertapenem in a 7-day hollow-fiber in vitro infection model
Tebipenem HBR
Descriptive epidemiology of UTI hospitalizations in the US, 2018
Tebipenem HBR
Empiric antimicrobial prescribing for urinary tract infections in patients discharged from the emergency department
Tebipenem HBR
Descriptive epidemiology and outcomes of emergency department visits with cUTI in the US, 2016-2018
Tebipenem HBR
Tebipenem in vitro activity against a collection of pathogens responsible for urinary tract infections in the US
Tebipenem HBR
An evaluation of tebipenem in vitro activity against a panel of Pseudomonas aeruginosa isolates with efflux, AmpC, and OprD mutations
Tebipenem HBR
In vitro activity of tebipenem, an orally available carbapenem agent, against a collection of surveillance gram-positive clinical isolates
Tebipenem HBR
Development of tebipenem MIC antimicrobial susceptibility test for gram-negative bacteria on MicroScan dried gram-negative MIC panels
Tebipenem HBR
Absorption, metabolism, and excretion of [14C]-tebipenem pivoxil hydrobromide (TBP-PI-HBr) following a single oral dose in healthy male subjects
Tebipenem HBR
In vitro activity of tebipenem against clinically significant gram-negative bacteria isolated from patients with cancer
Tebipenem HBR
Bioequivalence of two oral formulations of tebipenem-pivoxil hydrobromide in healthy subjects.
Tebipenem HBR
Effect of aluminum hydroxide/magnesium hydroxide/simethicone and omeprazole on the pharmacokinetics of tebipenem pivoxil hydrobromide (TBP-PI-HBr) in healthy adult subjects
Tebipenem HBR
Pharmacokinetics-pharmacodynamics evaluation of tebipenem pivoxil hydrobromide using the 10-day hollow-fiber in vitro infection model
Tebipenem HBR
In vitro activity of tebipenem against a recent collection of fastidious organisms recovered from respiratory tract infections
Tebipenem HBR
Medicare spending on urinary tract infections: a retrospective database analysis
Unable to find what you were looking for?
Download a complete bibliography from each of our ongoing investigational programs below.
